Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 Aug;118(8):2099–2106. doi: 10.1111/j.1476-5381.1996.tb15649.x

Effects of agents which elevate cyclic AMP on guinea-pig eosinophil homotypic aggregation.

M M Teixeira 1, A G Rossi 1, M A Giembycz 1, P G Hellewell 1
PMCID: PMC1909909  PMID: 8864548

Abstract

1. Eosinophil recruitment and activation in inflamed tissue is thought to play an important role in the pathophysiology of allergic diseases. Experimental evidence suggests that elevating cyclic AMP is an effective means of reducing eosinophil recruitment in vivo and may therefore have therapeutic benefit. In the present study, we have assessed the capacity of cyclic AMP-elevating agents to modulate guinea-pig eosinophil homotypic aggregation, a CD18-dependent process, which may be an important component of eosinophil function in vivo. 2. Prostaglandin E1 (PGE1, 10(-16) to 10(-6) M) inhibited platelet activating-factor (PAF)- and C5a-induced eosinophil aggregation in a concentration-dependent manner. However, PAF-induced responses were more potently and more effectively inhibited by PGE1. The inhibitory effects of PGE1 on PAF-induced aggregation were reversed by pretreatment of eosinophils with the protein kinase A inhibitors H89 and KT5720. 3. The beta 2-adrenoceptor agonists, salbutamol and salmeterol, concentration-dependently inhibited eosinophil aggregation induced by C5a and PAF and, again. PAF-induced responses were more effectively reduced. The inhibitory effect of salmeterol was mediated by beta-adrenoceptors, as assessed by the reversal after pretreatment with propranolol. 4. Rolipram, a selective phosphodiesterase 4 (PDE4) inhibitor, also attenuated PAF- and C5a-induced aggregation and at a low concentration which did not affect aggregation per se, had a synergistic effect with PGE1 and salbutamol to suppress this response. 5. Activation of eosinophils with PAF or C5a induced a small but significant increase in the level of CD18 expression on the eosinophil surface. PGE1 (10(-7) M) decreased PAF- and C5a-induced upregulation of CD18 by 93% and 62%, respectively. 6. These results demonstrate that cyclic AMP-elevating agents effectively inhibit eosinophil aggregation, a CD18-dependent functional response. Because CD18 has been shown to be important for eosinophil recruitment to inflamed tissue in vivo, our findings may be of relevance to the efficacy of cyclic AMP-elevating agents at inhibiting eosinophil trafficking.

Full text

PDF
2099

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ball D. I., Brittain R. T., Coleman R. A., Denyer L. H., Jack D., Johnson M., Lunts L. H., Nials A. T., Sheldrick K. E., Skidmore I. F. Salmeterol, a novel, long-acting beta 2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo. Br J Pharmacol. 1991 Nov;104(3):665–671. doi: 10.1111/j.1476-5381.1991.tb12486.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barnette M. S., Manning C. D., Cieslinski L. B., Burman M., Christensen S. B., Torphy T. J. The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity. J Pharmacol Exp Ther. 1995 May;273(2):674–679. [PubMed] [Google Scholar]
  3. Butchers P. R., Vardey C. J. The effect of prostanoids on the function of human eosinophils. Agents Actions Suppl. 1990;31:103–112. doi: 10.1007/978-3-0348-7379-6_12. [DOI] [PubMed] [Google Scholar]
  4. Corrigan C. J., Kay A. B. T cells and eosinophils in the pathogenesis of asthma. Immunol Today. 1992 Dec;13(12):501–507. doi: 10.1016/0167-5699(92)90026-4. [DOI] [PubMed] [Google Scholar]
  5. Das A. M., Williams T. J., Lobb R., Nourshargh S. Lung eosinophilia is dependent on IL-5 and the adhesion molecules CD18 and VLA-4, in a guinea-pig model. Immunology. 1995 Jan;84(1):41–46. [PMC free article] [PubMed] [Google Scholar]
  6. Dent G., Giembycz M. A., Evans P. M., Rabe K. F., Barnes P. J. Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol. J Pharmacol Exp Ther. 1994 Dec;271(3):1167–1174. [PubMed] [Google Scholar]
  7. Dent G., Giembycz M. A., Rabe K. F., Barnes P. J. Inhibition of eosinophil cyclic nucleotide PDE activity and opsonised zymosan-stimulated respiratory burst by 'type IV'-selective PDE inhibitors. Br J Pharmacol. 1991 Jun;103(2):1339–1346. doi: 10.1111/j.1476-5381.1991.tb09790.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Derian C. K., Santulli R. J., Rao P. E., Solomon H. F., Barrett J. A. Inhibition of chemotactic peptide-induced neutrophil adhesion to vascular endothelium by cAMP modulators. J Immunol. 1995 Jan 1;154(1):308–317. [PubMed] [Google Scholar]
  9. Diamond M. S., Springer T. A. The dynamic regulation of integrin adhesiveness. Curr Biol. 1994 Jun 1;4(6):506–517. doi: 10.1016/s0960-9822(00)00111-1. [DOI] [PubMed] [Google Scholar]
  10. Djukanović R., Roche W. R., Wilson J. W., Beasley C. R., Twentyman O. P., Howarth R. H., Holgate S. T. Mucosal inflammation in asthma. Am Rev Respir Dis. 1990 Aug;142(2):434–457. doi: 10.1164/ajrccm/142.2.434. [DOI] [PubMed] [Google Scholar]
  11. Dustin M. L., Springer T. A. T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1. Nature. 1989 Oct 19;341(6243):619–624. doi: 10.1038/341619a0. [DOI] [PubMed] [Google Scholar]
  12. Fügner A. Formation of oedema and accumulation of eosinophils in the guinea pig lung. Inhibition by inhaled beta-stimulants. Int Arch Allergy Appl Immunol. 1989;88(1-2):225–227. doi: 10.1159/000234792. [DOI] [PubMed] [Google Scholar]
  13. Giembycz M. A. Could isoenzyme-selective phosphodiesterase inhibitors render bronchodilator therapy redundant in the treatment of bronchial asthma? Biochem Pharmacol. 1992 May 28;43(10):2041–2051. doi: 10.1016/0006-2952(92)90160-k. [DOI] [PubMed] [Google Scholar]
  14. Gleich G. J., Adolphson C. R., Leiferman K. M. The biology of the eosinophilic leukocyte. Annu Rev Med. 1993;44:85–101. doi: 10.1146/annurev.me.44.020193.000505. [DOI] [PubMed] [Google Scholar]
  15. Hatzelmann A., Tenor H., Schudt C. Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions. Br J Pharmacol. 1995 Feb;114(4):821–831. doi: 10.1111/j.1476-5381.1995.tb13278.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Howell R. E., Sickels B. D., Woeppel S. L. Pulmonary antiallergic and bronchodilator effects of isozyme-selective phosphodiesterase inhibitors in guinea pigs. J Pharmacol Exp Ther. 1993 Feb;264(2):609–615. [PubMed] [Google Scholar]
  17. Kita H., Abu-Ghazaleh R. I., Gleich G. J., Abraham R. T. Regulation of Ig-induced eosinophil degranulation by adenosine 3',5'-cyclic monophosphate. J Immunol. 1991 Apr 15;146(8):2712–2718. [PubMed] [Google Scholar]
  18. Koenderman L., Kuijpers T. W., Blom M., Tool A. T., Roos D., Verhoeven A. J. Characteristics of CR3-mediated aggregation in human eosinophils: effect of priming by platelet-activating factor. J Allergy Clin Immunol. 1991 May;87(5):947–954. doi: 10.1016/0091-6749(91)90416-l. [DOI] [PubMed] [Google Scholar]
  19. Meurer R., Van Riper G., Feeney W., Cunningham P., Hora D., Jr, Springer M. S., MacIntyre D. E., Rosen H. Formation of eosinophilic and monocytic intradermal inflammatory sites in the dog by injection of human RANTES but not human monocyte chemoattractant protein 1, human macrophage inflammatory protein 1 alpha, or human interleukin 8. J Exp Med. 1993 Dec 1;178(6):1913–1921. doi: 10.1084/jem.178.6.1913. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Milne A. A., Piper P. J. The effects of two anti-CD18 antibodies on antigen-induced airway hyperresponsiveness and leukocyte accumulation in the guinea pig. Am J Respir Cell Mol Biol. 1994 Sep;11(3):337–343. doi: 10.1165/ajrcmb.11.3.7916197. [DOI] [PubMed] [Google Scholar]
  21. Munoz N. M., Vita A. J., Neeley S. P., McAllister K., Spaethe S. M., White S. R., Leff A. R. Beta adrenergic modulation of formyl-methionine-leucine-phenylalanine-stimulated secretion of eosinophil peroxidase and leukotriene C4. J Pharmacol Exp Ther. 1994 Jan;268(1):139–143. [PubMed] [Google Scholar]
  22. Muñoz N. M., Rabe K. F., Vita A. J., McAllister K., Mayer D., Weiss M., Leff A. R. Paradoxical blockade of beta adrenergically mediated inhibition of stimulated eosinophil secretion by salmeterol. J Pharmacol Exp Ther. 1995 May;273(2):850–854. [PubMed] [Google Scholar]
  23. Rabe K. F., Giembycz M. A., Dent G., Perkins R. S., Evans P., Barnes P. J. Salmeterol is a competitive antagonist at beta-adrenoceptors mediating inhibition of respiratory burst in guinea-pig eosinophils. Eur J Pharmacol. 1993 Feb 9;231(2):305–308. doi: 10.1016/0014-2999(93)90466-u. [DOI] [PubMed] [Google Scholar]
  24. Souness J. E., Carter C. M., Diocee B. K., Hassall G. A., Wood L. J., Turner N. C. Characterization of guinea-pig eosinophil phosphodiesterase activity. Assessment of its involvement in regulating superoxide generation. Biochem Pharmacol. 1991 Jul 25;42(4):937–945. doi: 10.1016/0006-2952(91)90056-b. [DOI] [PubMed] [Google Scholar]
  25. Souness J. E., Maslen C., Webber S., Foster M., Raeburn D., Palfreyman M. N., Ashton M. J., Karlsson J. A. Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram. Br J Pharmacol. 1995 May;115(1):39–46. doi: 10.1111/j.1476-5381.1995.tb16317.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Souness J. E., Scott L. C. Stereospecificity of rolipram actions on eosinophil cyclic AMP-specific phosphodiesterase. Biochem J. 1993 Apr 15;291(Pt 2):389–395. doi: 10.1042/bj2910389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Souness J. E., Villamil M. E., Scott L. C., Tomkinson A., Giembycz M. A., Raeburn D. Possible role of cyclic AMP phosphodiesterases in the actions of ibudilast on eosinophil thromboxane generation and airways smooth muscle tone. Br J Pharmacol. 1994 Apr;111(4):1081–1088. doi: 10.1111/j.1476-5381.1994.tb14855.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Teixeira M. M., Reynia S., Robinson M., Shock A., Williams T. J., Williams F. M., Rossi A. G., Hellewell P. G. Role of CD18 in the accumulation of eosinophils and neutrophils and local oedema formation in inflammatory reactions in guinea-pig skin. Br J Pharmacol. 1994 Mar;111(3):811–818. doi: 10.1111/j.1476-5381.1994.tb14810.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Teixeira M. M., Rossi A. G., Hellewell P. G. Adhesion mechanisms involved in C5a-induced eosinophil homotypic aggregation. J Leukoc Biol. 1996 Mar;59(3):389–396. doi: 10.1002/jlb.59.3.389. [DOI] [PubMed] [Google Scholar]
  30. Teixeira M. M., Rossi A. G., Williams T. J., Hellewell P. G. Effects of phosphodiesterase isoenzyme inhibitors on cutaneous inflammation in the guinea-pig. Br J Pharmacol. 1994 May;112(1):332–340. doi: 10.1111/j.1476-5381.1994.tb13073.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Teixeira M. M., Williams T. J., Au B. T., Hellewell P. G., Rossi A. G. Characterization of eosinophil homotypic aggregation. J Leukoc Biol. 1995 Feb;57(2):226–234. doi: 10.1002/jlb.57.2.226. [DOI] [PubMed] [Google Scholar]
  32. Teixeira M. M., Williams T. J., Hellewell P. G. Anti-inflammatory effects of a short-acting and a long-acting beta 2-adrenoceptor agonist in guinea pig skin. Eur J Pharmacol. 1995 Jan 16;272(2-3):185–193. doi: 10.1016/0014-2999(94)00643-l. [DOI] [PubMed] [Google Scholar]
  33. Teixeira M. M., Williams T. J., Hellewell P. G. E-type prostaglandins enhance local oedema formation and neutrophil accumulation but suppress eosinophil accumulation in guinea-pig skin. Br J Pharmacol. 1993 Sep;110(1):416–422. doi: 10.1111/j.1476-5381.1993.tb13826.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Ting S., Zweiman B., Lavker R. Terbutaline modulation of human allergic skin reactions. J Allergy Clin Immunol. 1983 May;71(5):437–441. doi: 10.1016/0091-6749(83)90458-x. [DOI] [PubMed] [Google Scholar]
  35. Torphy T. J., Undem B. J. Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax. 1991 Jul;46(7):512–523. doi: 10.1136/thx.46.7.512. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Underwood D. C., Kotzer C. J., Bochnowicz S., Osborn R. R., Luttmann M. A., Hay D. W., Torphy T. J. Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs. J Pharmacol Exp Ther. 1994 Jul;270(1):250–259. [PubMed] [Google Scholar]
  37. Underwood D. C., Osborn R. R., Novak L. B., Matthews J. K., Newsholme S. J., Undem B. J., Hand J. M., Torphy T. J. Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram. J Pharmacol Exp Ther. 1993 Jul;266(1):306–313. [PubMed] [Google Scholar]
  38. Whelan C. J., Johnson M. Inhibition by salmeterol of increased vascular permeability and granulocyte accumulation in guinea-pig lung and skin. Br J Pharmacol. 1992 Apr;105(4):831–838. doi: 10.1111/j.1476-5381.1992.tb09065.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Zeck-Kapp G., Kroegel C., Riede U. N., Kapp A. Mechanisms of human eosinophil activation by complement protein C5a and platelet-activating factor: similar functional responses are accompanied by different morphologic alterations. Allergy. 1995 Jan;50(1):34–47. doi: 10.1111/j.1398-9995.1995.tb02481.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES